KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Short term Debt: 2009-2024

Historic Short term Debt for Biomarin Pharmaceutical (BMRN) over the last 10 years, with Jun 2024 value amounting to $494.8 million.

  • Biomarin Pharmaceutical's Short term Debt was N/A to $494.8 million in Q2 2024 from the same period last year, while for Jun 2024 it was $494.8 million, marking a year-over-year change of. This contributed to the annual value of $493.9 million for FY2023, which is 3001.27% up from last year.
  • Biomarin Pharmaceutical's Short term Debt amounted to $494.8 million in Q2 2024, which was up 0.10% from $494.4 million recorded in Q1 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's Short term Debt peaked at $494.8 million during Q2 2024, and registered a low of $15.9 million during Q4 2022.
  • For the 3-year period, Biomarin Pharmaceutical's Short term Debt averaged around $264.3 million, with its median value being $278.7 million (2022).
  • Per our database at Business Quant, Biomarin Pharmaceutical's Short term Debt skyrocketed by 3,642.90% in 2020 and then tumbled by 91.58% in 2021.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Short term Debt stood at $374.3 million in 2020, then plummeted by 87.12% to $48.2 million in 2021, then plummeted by 66.98% to $15.9 million in 2022, then skyrocketed by 3,001.27% to $493.9 million in 2023, then reached $494.8 million in 2024.
  • Its Short term Debt stands at $494.8 million for Q2 2024, versus $494.4 million for Q1 2024 and $493.9 million for Q4 2023.